Medicare Enrolled

Dr. Quratul Raja, MD

Rheumatology · Sugar Land, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
16659 SOUTHWEST FWY STE 461, Sugar Land, TX 77479
2819802717
In practice since 2009 (16 years)
NPI: 1497089460 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Raja from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Raja? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Raja

Dr. Quratul Raja is a rheumatology specialist in Sugar Land, TX, with 16 years of NPI registration. Based on federal Medicare data, Dr. Raja performed 3,960 Medicare services across 538 unique beneficiaries.

Between the years covered by Open Payments, Dr. Raja received a total of $3,568 from 14 pharmaceutical and/or device companies across 189 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Raja is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 16 years in practice ▲ Top 46% volume in TX $3,568 industry payments

Medicare Practice Summary

Medicare Utilization ↗
3,960
Medicare services
Top 46% in TX for rheumatology
538
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~248 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 2,220 $17 $24
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
1,040 $26 $75
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
187 $85 $177
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
89 $1 $20
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
78 $11 $94
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
69 $22 $55
New patient office visit, complex (60-74 min) 59 $164 $416
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
56 $98 $191
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
46 $47 $175
X-ray of hand, minimum of 3 views
An X-ray imaging test of the hand that captures at least three different angles to visualize the bones and joints.
26 $22 $49
Methylprednisolone acetate injection, 80 mg
An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication.
24 $9 $19
Foot X-ray, 3+ views
An X-ray imaging test of the foot that captures at least three different views to evaluate the bones and joints.
21 $19 $49
Intravenous drug injection
A procedure involving the administration of a medication or substance directly into a vein.
18 $29 $95
Bone density scan (DEXA) of hip, pelvis, and spine
This test measures bone density in the hip, pelvis, and spine to assess bone strength. It also includes an assessment for spine fractures.
16 $50 $100
Trabecular bone score calculation
This procedure calculates the trabecular bone score using imaging data to assess bone microarchitecture. It includes interpretation and a report on fracture risk.
11 $29 $70
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
31.1% high complexity
60.8% medium
8.1% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$3,568
Total received (2018-2024)
Avg $595/year across 6 years
Bottom 44% in TX for rheumatology
14
Companies
189
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,468 (97.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$100 (2.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,555
2023
$919
2022
$385
2021
$148
2020
$257
2018
$304

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$703
Amgen Inc.
$664
Janssen Biotech, Inc.
$482
PFIZER INC.
$437
Novartis Pharmaceuticals Corporation
$214
UCB, Inc.
$172
Lilly USA, LLC
$156
Radius Health, Inc.
$131
AstraZeneca Pharmaceuticals LP
$113
AbbVie Inc.
$112
Aurinia Pharma U.S., Inc.
$104
GlaxoSmithKline, LLC.
$103
Genentech USA, Inc.
$100
E.R. Squibb & Sons, L.L.C.
$77
Top 3 companies account for 51.8% of total payments
Associated products mentioned in payments ›
Actemra · BENLYSTA · Bimzelx · COSENTYX · Cimzia · EVENITY · Enbrel · HUMIRA · ILARIS · KRYSTEXXA · LUPKYNIS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ORENCIA · Otezla · REMICADE · RINVOQ · SAPHNELO · SIMPONI ARIA · SKYRIZI · TALTZ · TAVNEOS · TREMFYA · Tymlos · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $90 per 100 Medicare services performed
Looking for a rheumatology specialist in Sugar Land?
Compare rheumatologists in the Sugar Land area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
64
Per 100K population
7.4
County median income
$113,409
Nearest hospital
HOUSTON METHODIST SUGARLAND HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Raja is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 16 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Raja experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Raja performed 2,220 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Raja receive payments from pharmaceutical companies?
Yes. Dr. Raja received a total of $3,568 from 14 companies across 189 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Raja's costs compare to other rheumatologists in Sugar Land?
Dr. Raja's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Raja) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →